Pharmacokinetic-Pharmacodynamic Analysis of the EEG Effect of Alfentanil in Rats Followingβ-Funaltrexamine-Induced μOpioid Receptor “Knockdown”In Vivo (original) (raw)
Abstract
Purpose. The objective of this investigation was to determine theinfluence of pre-treatment with the irreversible μ-opioid receptorantagonist β-funaltrexamine (β-FNA) on thepharmacokinetic-pharmacodynamic (PK/PD) relationship of alfentanil in rats.
Methods. The PK/PD correlation of alfentanil (2 mg.kg−1intravenously in 20 min) was determined in chronically instrumented ratsusing amplitudes in the 0.5–4.5 Hz frequency band of the EEG aspharmacodynamic endpoint. β-FNA was administered intravenously(10 mg.kg−1) either 35 min or 24 h prior to the PK/PD experiments.
Results. Pre-treatment with β-FNA had no influence on thepharmacokinetics of alfentanil. The in vivo concentration-EEG effectrelationships, however, were steeper and shifted towards higher concentrationswith no difference between the 35-min and the 24-h pre-treatmentgroups. Analysis of the data on basis of the operational model agonismrevealed that the observed changes could be explained by a 70–80%reduction in alfentanil efficacy in β-FNA pre-treated rats. This isconsistent with results from an in vitro receptor bioassay showing a40–60% reduction in the number of specific μ-opioid binding sites inthe brain.
Conclusions. This investigation confirms the validity of a previouslypostulated mechanism-based PK/PD model for the effect of syntheticopiates in rats.
Access this article
Subscribe and save
- Get 10 units per month
- Download Article/Chapter or eBook
- 1 Unit = 1 Article or 1 Chapter
- Cancel anytime Subscribe now
Buy Now
Price excludes VAT (USA)
Tax calculation will be finalised during checkout.
Instant access to the full article PDF.
Similar content being viewed by others
REFERENCES
- M. Ekblom, M. Hammeralund-Udenaes, and L. K. Paalzow. Modelling of tolerance development and rebound effect during different intravenous administrations of morphine to rats. J. Pharmacol. Exp. Ther. 266:244–252 (1993).
Google Scholar - J. W. Mandema and D. R. Wada. Pharmacodynamic model for acute tolerance development to the electroencephalographic effects of alfentanil in the rat. J. Pharmacol. Exp. Ther. 275: 1185–1194 (1995).
Google Scholar - D. E. Keith, B. Anton, S. R. Murray, P. A. Zaki, P. C. Chu, D. V. Lissin, G. Monteillet-Agius, P. L. Stewart, C. J. Evans, and M. Von Zastrow. μ-opioid receptor internalization: opiate drugs have differential effects on a conserved endocytic mechanism in vitro and in the mammalian brain. Mol. Pharmacol. 53:377–384 (1998).
Google Scholar - F. Sehba, A. Duttaroy, S. Shah, B. Chen, J. Carroll, and B. C. Yoburn. In vivo homologous regulation of μ-opioid receptor gene expression in the mouse. Eur. J. Pharmacol. 339:33–41 (1997).
Google Scholar - B. L. Kieffer. Opioids: first lessons from knockout mice. Trends Pharmacol. Sci. 20:19–26 (1999).
Google Scholar - E. H. Cox, T. Kerbusch, P. H. Van der Graaf, and M. Danhof. Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effect of synthetic opioids in the rat: correlation with the interaction at the _m_u-opioid receptor. J. Pharmacol. Exp. Ther. 284:1095–1103 (1998a).
Google Scholar - J. W. Black, and P. Leff. Operational models of pharmacological agonism. Proc. R. Soc. Lond. B. 220:141–162 (1983).
Google Scholar - E. H. Cox, J. A. Kuipers, and M. Danhof. Pharmacokinetic-pharmacodynamic modeling of the EEG effect of alfentanil in rats: assessment of rapid functional adaptation. Br. J. Pharmacol. 124:1534–1540 (1998b).
Google Scholar - P. S. Portoghese, D. L. Larson, L. M. Sayre, D. S. Fries, and A. E. Takemori. A novel opioid receptor site directed alkylating agent with irreversible narcotic antagonistic and reversible agonistic activities. J. Med. Chem. 23:233–234 (1980).
Google Scholar - E. H. Cox, J. G. N. van Hemert, E. J. Tukker, and M. Danhof. Pharmacokinetic-pharmacodynamic modelling of the EEG effect of alfentanil in rats. J. Pharmacol. Toxicol. Meth. 38:99–108 (1997).
Google Scholar - R. C. Schoemaker and A. F. Cohen. Estimating impossible curves using NONMEM. Br. J. Clin. Pharmacol. 42:283–290 (1996).
Google Scholar - P. H. Van der Graaf, E. A. Van Schaick, R. A. A. Mathô t, A. P. IJzerman, and M. Danhof. Mechanism-based pharmacokinetic-pharmacodynamic modeling of the effects of N6-cyclopentyladenosine analogs on heart rate in rat: estimation of in vivo operational affinity and efficacy at adenosine A1 receptors. J. Pharmacol. Exp. Ther. 283:809–816 (1997).
Google Scholar - P. H. Van der Graaf, E. A. Van Schaick, S. A. G. Visser, H. J. M. M. De Greef, A. P. IJzerman, and M. Danhof. Mechanism-based pharmacokinetic-pharmacodynamic modeling of anti-lipolytic effects of adenosine A1 receptor agonists in rats: prediction of tissue-dependent efficacy in vivo. J. Pharmacol. Exp. Ther. 290:702–709 (1999).
Google Scholar - Y-C. Cheng and W. H. Prusoff. Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50 percent inhibition (I50) of an enzymatic reaction. Biochem. Pharmacol. 22:3099–3108 (1973).
Google Scholar - A. Christopoulos. Assessing the distribution of parameters in models of ligand-receptor interaction: to log or not to log. Trends Pharmacol. Sci. 19:351–357 (1998).
Google Scholar - P. H. Van der Graaf and M. Danhof. On the reliability of affinity and efficacy estimates obtained by direct operational model fitting of agonist concentration-effect curves following irreversible receptor inactivation. J. Pharmacol. Toxicol. Meth. 38:81–85 (1997).
Google Scholar - R. B. Rothman, J. B. Long, V. Bykov, A. E. Jacobson, K. C. Rice and H. W. Holaday. β-FNA binds irreversible to the opiate receptor complex: in vivo and in vitro evidence. J. Pharmacol. Exp. Ther. 247:405–416 (1988).
Google Scholar - C. Chen, J-C. Xue, J. Zhu, Y-W. Chen, S. Kunapuli, J. K. De Riel, and L-Y. Liu-Chen. Characterization of irreversible binding of β-funaltrexanine to the cloned rat μ-opioid receptor. J. Biol. Chem. 270:17866–17870 (1995).
Google Scholar - J. Giraldo. The slope parameter and the receptor reserve. Trends Pharmacol. Sci. 19:445 (1998)
Google Scholar - J. W. Black, P. Leff, and N. P. Shankley, with an appendix by J. Wood. An operational model of pharmacological agonism: the effect of E/[A] curve shape on agonist dissociation constant estimation. Br. J. Pharmacol. 84:561–571 (1985).
Google Scholar - P. H. Van der Graaf, N. P. Shankley, and J. W. Black. Analysis of the activity of α1-adrenoceptor antagonists in rat aorta. Br. J. Pharmacol. 118:299–310 (1996).
Google Scholar - G. Zernig, E. R. Butelman, J. W. Lewis, E. A. Walker, and J. H. Woods. In vivo determination of the μ-opioid receptor turnover in monkeys after irreversible blockade with clocinnamex. J. Pharmacol. Exp. Ther. 269:57–65 (1994).
Google Scholar - Y-X. Pan, J. Xu, E. Bolau, C. Abbadie, A. Chang, A. Zuckerman, G. Rossi, and G. W. Pasternak. Identification and characterization of three new alternatively spliced μ-opioid receptor isoforms. Mol. Pharmacol. 56:396–403 (1999).
Google Scholar - G. Zernig, T. Burke, J. W. Lewis and J. H. Woods. Mechanism of clocinnamoxblockade of opioid receptors: evidence from in vitro and ex vivo binding and behavioral assays. J. Pharmacol. Exp. Ther. 279:23–31 (1996).
Google Scholar - T. Koch, S. Schulz, H. Schröder, R. Wolf, E. Raulf, and V. Hölt. Carboxyl-terminal splicing of the rat ? opioid receptor modulates agonist-mediated internalization and receptor resensitization. J. Biol. Chem. 273:13652–13657 (1998).
Google Scholar - R. Wolf, T. Koch, S. Schulz, M. Klutzny, H. Schröder, E. Raulf, F. Bühling, and V. Höllt. Replacement of threonine 394 by alanine facilitates internalization and resensitization of the rat ? opioid receptor. Mol. Pharmacol. 55:263–268 (1999).
Google Scholar - D. Morgan and M. J. Picker. The μ opioid irreversible antagonist beta-funaltrexamine differentiates the discriminative stimulus effects of opioids with high and low efficacy at the μ opioid receptor. Psychopharmacol. 140:20–28 (1998).
Google Scholar
Author information
Authors and Affiliations
- Division of Pharmacology, Leiden Amsterdam Center for Drug Research, P.O. Box 9503, 2300 RA, Leiden, The Netherlands
>Maria Garrido, Josy Gubbens-Stibbe, Erica Tukker, Eugégne Cox, Jacobien von Frijtag & Piet H. van der Graaf - Division of Medicinal Chemistry, Leiden Amsterdam Center for Drug Research, P.O. Box 9502, 2300 RA, Leiden, The Netherlands
Jacobien von Frijtag, DrabbeM Künzel & Ad IJzerman - Discovery Biology, Pfizer Central Research, Ramsgate Road, Sandwich, Kent, CT13 9NJ, United Kingdom
Jacobien von Frijtag & Piet H. van der Graaf - Division of Pharmacology, Leiden Amsterdam Center for Drug Research, P.O. Box 9503, 2300 RA, Leiden, The Netherlands
Jacobien von Frijtag & Meindert Danhof
Authors
- >Maria Garrido
You can also search for this author inPubMed Google Scholar - Josy Gubbens-Stibbe
You can also search for this author inPubMed Google Scholar - Erica Tukker
You can also search for this author inPubMed Google Scholar - Eugégne Cox
You can also search for this author inPubMed Google Scholar - Jacobien von Frijtag
You can also search for this author inPubMed Google Scholar - DrabbeM Künzel
You can also search for this author inPubMed Google Scholar - Meindert Danhof
You can also search for this author inPubMed Google Scholar - Piet H. van der Graaf
You can also search for this author inPubMed Google Scholar
Rights and permissions
About this article
Cite this article
Garrido, >., Gubbens-Stibbe, J., Tukker, E. et al. Pharmacokinetic-Pharmacodynamic Analysis of the EEG Effect of Alfentanil in Rats Followingβ-Funaltrexamine-Induced μOpioid Receptor “Knockdown”In Vivo.Pharm Res 17, 653–659 (2000). https://doi.org/10.1023/A:1007513812018
- Issue Date: June 2000
- DOI: https://doi.org/10.1023/A:1007513812018